BioXcel Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 09:40PM GMT
Corinne Jenkins - Goldman Sachs Group, Inc., Research Division - VP

Great. Welcome, everyone, and welcome, especially to the team from BioXcel Therapeutics. Today, we have Vimal Mehta, CEO; Rob Risinger, CMO; and then we've got Matt Wiley, Chief Commercial Officer. So thanks to all of you for joining, and thanks to everyone who's joining us here and on the webcast.

Questions and Answers:

Corinne Jenkins - Goldman Sachs Group, Inc., Research Division - VP

Maybe just to start, could you level set with a brief overview of the company with perhaps a particular focus on what you see as key value drivers over the next 12 to 24 months?

Vimal D. Mehta - BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director

Great. Thank you, Corinne, for hosting us, and good afternoon, everyone. BioXcel Therapeutics is a biopharmaceutical company developing innovative medicines in neuroscience and immuno-oncology using artificial intelligence-based platform.

In terms of where we are, we've been now, like a public
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot